Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic, C. Hunter, B. Z. Dolimbek, G. S. Dolimbek, C. H. Adler, A. Brashear, C. L. Comella, M. Gordon, D. E. Riley, Kapil Dev Sethi, C. Singer, M. Stacy, D. Tarsy, M. Z. Atassi

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Original languageEnglish (US)
Pages (from-to)2233-2235
Number of pages3
JournalNeurology
Volume67
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Torticollis
Blocking Antibodies
Antibodies
Therapeutics
Multicenter Studies
rimabotulinumtoxinB

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Jankovic, J., Hunter, C., Dolimbek, B. Z., Dolimbek, G. S., Adler, C. H., Brashear, A., ... Atassi, M. Z. (2006). Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology, 67(12), 2233-2235. https://doi.org/10.1212/01.wnl.0000249308.66959.43

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. / Jankovic, J.; Hunter, C.; Dolimbek, B. Z.; Dolimbek, G. S.; Adler, C. H.; Brashear, A.; Comella, C. L.; Gordon, M.; Riley, D. E.; Sethi, Kapil Dev; Singer, C.; Stacy, M.; Tarsy, D.; Atassi, M. Z.

In: Neurology, Vol. 67, No. 12, 01.12.2006, p. 2233-2235.

Research output: Contribution to journalArticle

Jankovic, J, Hunter, C, Dolimbek, BZ, Dolimbek, GS, Adler, CH, Brashear, A, Comella, CL, Gordon, M, Riley, DE, Sethi, KD, Singer, C, Stacy, M, Tarsy, D & Atassi, MZ 2006, 'Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia', Neurology, vol. 67, no. 12, pp. 2233-2235. https://doi.org/10.1212/01.wnl.0000249308.66959.43
Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 1;67(12):2233-2235. https://doi.org/10.1212/01.wnl.0000249308.66959.43
Jankovic, J. ; Hunter, C. ; Dolimbek, B. Z. ; Dolimbek, G. S. ; Adler, C. H. ; Brashear, A. ; Comella, C. L. ; Gordon, M. ; Riley, D. E. ; Sethi, Kapil Dev ; Singer, C. ; Stacy, M. ; Tarsy, D. ; Atassi, M. Z. / Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. In: Neurology. 2006 ; Vol. 67, No. 12. pp. 2233-2235.
@article{fa1d9cbcf646492c865546b45557fb09,
title = "Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia",
abstract = "In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.",
author = "J. Jankovic and C. Hunter and Dolimbek, {B. Z.} and Dolimbek, {G. S.} and Adler, {C. H.} and A. Brashear and Comella, {C. L.} and M. Gordon and Riley, {D. E.} and Sethi, {Kapil Dev} and C. Singer and M. Stacy and D. Tarsy and Atassi, {M. Z.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1212/01.wnl.0000249308.66959.43",
language = "English (US)",
volume = "67",
pages = "2233--2235",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

AU - Jankovic, J.

AU - Hunter, C.

AU - Dolimbek, B. Z.

AU - Dolimbek, G. S.

AU - Adler, C. H.

AU - Brashear, A.

AU - Comella, C. L.

AU - Gordon, M.

AU - Riley, D. E.

AU - Sethi, Kapil Dev

AU - Singer, C.

AU - Stacy, M.

AU - Tarsy, D.

AU - Atassi, M. Z.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

AB - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

UR - http://www.scopus.com/inward/record.url?scp=33845939760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845939760&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000249308.66959.43

DO - 10.1212/01.wnl.0000249308.66959.43

M3 - Article

VL - 67

SP - 2233

EP - 2235

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -